PTAB Rejects AIA Challenge To Amgen Drug Patent
The Patent Trial and Appeal Board decided Wednesday not to review an Amgen hyperparathyroidism drug patent, ruling the challenger, an entity Amgen alleged was formed months before the petition was filed and...To view the full article, register now.
Already a subscriber? Click here to view full article